KR102302580B1 - Cxcr7 수용체 조절제 - Google Patents

Cxcr7 수용체 조절제 Download PDF

Info

Publication number
KR102302580B1
KR102302580B1 KR1020157036801A KR20157036801A KR102302580B1 KR 102302580 B1 KR102302580 B1 KR 102302580B1 KR 1020157036801 A KR1020157036801 A KR 1020157036801A KR 20157036801 A KR20157036801 A KR 20157036801A KR 102302580 B1 KR102302580 B1 KR 102302580B1
Authority
KR
South Korea
Prior art keywords
ethyl
tetrahydro
isoquinolin
acetamide
benzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020157036801A
Other languages
English (en)
Korean (ko)
Other versions
KR20160013197A (ko
Inventor
하인츠 프레츠
필리쁘 귀리
티에리 깽메를랭
프랑수아 레앙브르
줄리앙 포띠에
에르브 시앙드
안야 팔데나이레
Original Assignee
이도르시아 파마슈티컬스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이도르시아 파마슈티컬스 리미티드 filed Critical 이도르시아 파마슈티컬스 리미티드
Publication of KR20160013197A publication Critical patent/KR20160013197A/ko
Application granted granted Critical
Publication of KR102302580B1 publication Critical patent/KR102302580B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
KR1020157036801A 2013-05-30 2014-05-28 Cxcr7 수용체 조절제 Expired - Fee Related KR102302580B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IB2013054478 2013-05-30
IBPCT/IB2013/054478 2013-05-30
PCT/IB2014/061774 WO2014191929A1 (en) 2013-05-30 2014-05-28 Cxcr7 receptor modulators

Publications (2)

Publication Number Publication Date
KR20160013197A KR20160013197A (ko) 2016-02-03
KR102302580B1 true KR102302580B1 (ko) 2021-09-15

Family

ID=50943357

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157036801A Expired - Fee Related KR102302580B1 (ko) 2013-05-30 2014-05-28 Cxcr7 수용체 조절제

Country Status (30)

Country Link
US (1) US9920010B2 (cg-RX-API-DMAC10.html)
EP (1) EP3004082B1 (cg-RX-API-DMAC10.html)
JP (1) JP6393749B2 (cg-RX-API-DMAC10.html)
KR (1) KR102302580B1 (cg-RX-API-DMAC10.html)
CN (1) CN105263924B (cg-RX-API-DMAC10.html)
AR (1) AR096490A1 (cg-RX-API-DMAC10.html)
AU (1) AU2014272718B2 (cg-RX-API-DMAC10.html)
BR (1) BR112015030095B1 (cg-RX-API-DMAC10.html)
CA (1) CA2912133C (cg-RX-API-DMAC10.html)
CL (1) CL2015003470A1 (cg-RX-API-DMAC10.html)
CY (1) CY1119537T1 (cg-RX-API-DMAC10.html)
DK (1) DK3004082T3 (cg-RX-API-DMAC10.html)
EA (1) EA028604B1 (cg-RX-API-DMAC10.html)
ES (1) ES2645470T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20171597T1 (cg-RX-API-DMAC10.html)
HU (1) HUE036649T2 (cg-RX-API-DMAC10.html)
IL (1) IL242782B (cg-RX-API-DMAC10.html)
LT (1) LT3004082T (cg-RX-API-DMAC10.html)
MA (1) MA38679B1 (cg-RX-API-DMAC10.html)
MX (1) MX364104B (cg-RX-API-DMAC10.html)
MY (1) MY173564A (cg-RX-API-DMAC10.html)
NO (1) NO3004082T3 (cg-RX-API-DMAC10.html)
PH (1) PH12015502632B1 (cg-RX-API-DMAC10.html)
PL (1) PL3004082T3 (cg-RX-API-DMAC10.html)
PT (1) PT3004082T (cg-RX-API-DMAC10.html)
SG (1) SG11201509057UA (cg-RX-API-DMAC10.html)
SI (1) SI3004082T1 (cg-RX-API-DMAC10.html)
TW (1) TWI640510B (cg-RX-API-DMAC10.html)
UA (1) UA118562C2 (cg-RX-API-DMAC10.html)
WO (1) WO2014191929A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR091516A1 (es) 2012-06-22 2015-02-11 Actelion Pharmaceuticals Ltd Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida
US10202368B2 (en) 2014-12-01 2019-02-12 Idorsia Pharmaceuticals Ltd. CXCR7 receptor modulators
US20170112831A1 (en) * 2015-10-23 2017-04-27 James MERRITT Use of ccr1 antagonists as a treatment for tumors of the central nervous system
EP3490986B1 (en) * 2016-07-28 2021-11-24 Idorsia Pharmaceuticals Ltd Piperidine cxcr7 receptor modulators
AR111808A1 (es) 2017-05-18 2019-08-21 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
EA201992676A1 (ru) 2017-05-18 2020-05-06 Идорсия Фармасьютиклз Лтд Фенильные производные в качестве модуляторов pge2 рецепторов
KR102502046B1 (ko) 2018-01-26 2023-02-20 이도르시아 파마슈티컬스 리미티드 Cxcr7 수용체 작동제 (3s,4s)-1-시클로프로필메틸-4-{[5-(2,4-디플루오로-페닐)-이속사졸-3-카르보닐]-아미노}-피페리딘-3-카르복실산 (1-피리미딘-2-일-시클로프로필)-아미드의 결정질 형태

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004058705A2 (en) 2002-12-20 2004-07-15 Chemocentryx Inhibitors of the binding of chemokines i-tac or sdf-1 to the ccxckr2 receptor
WO2007059108A2 (en) 2005-11-10 2007-05-24 Chemocentryx, Inc. Substituted quinolones and methods of use
WO2013190508A2 (en) 2012-06-22 2013-12-27 Actelion Pharmaceuticals Ltd 1-[m-carboxamido(hetero)aryl-methyl]-heterocyclyl-carboxamide derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896170A (en) 1969-02-26 1975-07-22 American Home Prod Intermediates for the preparation of 1,3-dihydro-2h-1, -benzodiazepin-2-ones
RU2214405C2 (ru) 1998-02-18 2003-10-20 НьюроСёрч А/С Новые соединения и их применение в качестве положительных модуляторов амра-рецепторов
GB9816984D0 (en) * 1998-08-05 1998-09-30 Smithkline Beecham Plc Novel compounds
US7256201B2 (en) 2000-12-07 2007-08-14 Astrazeneca Ab Selective estrogen receptor-β ligands
US20100331298A1 (en) 2007-12-10 2010-12-30 Cytopathfinder, Inc. Carboxamide Compounds and Their Use
US10202368B2 (en) 2014-12-01 2019-02-12 Idorsia Pharmaceuticals Ltd. CXCR7 receptor modulators

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004058705A2 (en) 2002-12-20 2004-07-15 Chemocentryx Inhibitors of the binding of chemokines i-tac or sdf-1 to the ccxckr2 receptor
WO2007059108A2 (en) 2005-11-10 2007-05-24 Chemocentryx, Inc. Substituted quinolones and methods of use
WO2013190508A2 (en) 2012-06-22 2013-12-27 Actelion Pharmaceuticals Ltd 1-[m-carboxamido(hetero)aryl-methyl]-heterocyclyl-carboxamide derivatives

Also Published As

Publication number Publication date
PH12015502632A1 (en) 2016-03-07
MY173564A (en) 2020-02-04
LT3004082T (lt) 2017-10-25
EA028604B1 (ru) 2017-12-29
MA38679B1 (fr) 2019-12-31
PT3004082T (pt) 2017-11-13
HUE036649T2 (hu) 2018-07-30
SG11201509057UA (en) 2015-12-30
US9920010B2 (en) 2018-03-20
KR20160013197A (ko) 2016-02-03
AU2014272718B2 (en) 2018-06-28
BR112015030095B1 (pt) 2023-02-28
JP6393749B2 (ja) 2018-09-19
AU2014272718A1 (en) 2016-01-21
DK3004082T3 (en) 2017-10-02
WO2014191929A1 (en) 2014-12-04
CN105263924B (zh) 2018-10-19
EP3004082A1 (en) 2016-04-13
ES2645470T3 (es) 2017-12-05
EA201501163A1 (ru) 2016-06-30
CY1119537T1 (el) 2018-03-07
IL242782A0 (en) 2016-02-01
PL3004082T3 (pl) 2018-01-31
CA2912133C (en) 2021-06-22
US20160107997A1 (en) 2016-04-21
NZ715530A (en) 2020-12-18
HK1223353A1 (en) 2017-07-28
NO3004082T3 (cg-RX-API-DMAC10.html) 2017-12-30
CL2015003470A1 (es) 2016-06-17
TW201529557A (zh) 2015-08-01
EP3004082B1 (en) 2017-08-02
UA118562C2 (uk) 2019-02-11
MA38679A1 (fr) 2018-07-31
AR096490A1 (es) 2016-01-13
MX2015016429A (es) 2016-03-01
BR112015030095A2 (pt) 2022-07-12
IL242782B (en) 2019-06-30
MX364104B (es) 2019-04-12
HRP20171597T1 (hr) 2017-12-01
SI3004082T1 (sl) 2017-11-30
CN105263924A (zh) 2016-01-20
JP2016520120A (ja) 2016-07-11
PH12015502632B1 (en) 2016-03-07
TWI640510B (zh) 2018-11-11
CA2912133A1 (en) 2014-12-04

Similar Documents

Publication Publication Date Title
KR101646858B1 (ko) 아제티딘 화합물, 조성물 및 가용성 에폭사이드 가수분해효소의 억제제로서의 이의 용도
TWI691497B (zh) 哌啶衍生物
DK3004082T3 (en) CXCR7 RECEPTOR MODULATORS
EP3227263B1 (en) Cxcr7 receptor modulators
WO2017201069A1 (en) Oxoindoline derivatives as protein function modulators
EP1682545B1 (en) Imidazopyridine substituted tropane derivatives with ccr5 receptor antagonist activity for the treatment of hiv and inflammation
JP2007513181A (ja) 新規m3ムスカリン性アセチルコリン受容体アンタゴニスト
JP2007504159A (ja) プロテインキナーゼ阻害剤としての化合物および組成物
US20050222186A1 (en) Substituted diaminopyrimidines
JP7076010B2 (ja) (3s,4s)-1-シクロプロピルメチル-4-{[5-(2,4-ジフルオロ-フェニル)-イソオキサゾール-3-カルボニル]-アミノ}-ピペリジン-3-カルボン酸 (1-ピリミジン-2-イル-シクロプロピル)-アミドの結晶形
HK1223353B (en) Cxcr7 receptor modulators
NZ715530B2 (en) Cxcr7 receptor modulators
HK40040315A (en) Crystalline forms of the cxcr7 receptor antagonist (3s,4s)-1-cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20240910

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20240910